APA (7th ed.) Citation

Ogata, Y., Sadahiro, S., Sakamoto, K., Tsuchiya, T., Takahashi, T., Ohge, H., . . . Morita, S. (2024). Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201). International Journal of Clinical Oncology, 29(9), 1284-1292. https://doi.org/10.1007/s10147-024-02565-5

Chicago Style (17th ed.) Citation

Ogata, Yutaka, et al. "Final Analyses of the Prospective Controlled Trial on the Efficacy of Uracil and Tegafur/leucovorin as an Adjuvant Treatment for Stage II Colon Cancer with Risk Factors for Recurrence Using Propensity Score-based Methods (JFMC46-1201)." International Journal of Clinical Oncology 29, no. 9 (2024): 1284-1292. https://doi.org/10.1007/s10147-024-02565-5.

MLA (9th ed.) Citation

Ogata, Yutaka, et al. "Final Analyses of the Prospective Controlled Trial on the Efficacy of Uracil and Tegafur/leucovorin as an Adjuvant Treatment for Stage II Colon Cancer with Risk Factors for Recurrence Using Propensity Score-based Methods (JFMC46-1201)." International Journal of Clinical Oncology, vol. 29, no. 9, 2024, pp. 1284-1292, https://doi.org/10.1007/s10147-024-02565-5.